PPQ or PRredicTor, a subset of NETest analytes, deliver 94% accuracy in predicting response to Peptide Receptor Radionuclide Therapy
We developed a complementary diagnostic based on circulating gene expression measurements (Ome index) and grading which can be used to predict response to PRRT. The accuracy of this Prediction Quotient in this discovery cohort of 54 NETs was 94%...
NET patients are increasingly treated with peptide receptor radionuclide therapy. Somatostatin receptor expression evaluation cannot predict who will respond to therapy. But research indicates NETest PPQ can predict PRRT response.
We validated the PRRT Prediction Quotient (PPQ) as a complementary diagnostic in two different PRRT cohorts. The validation cohort prediction accuracy was 95%; significantly more predictive than either grade (70%) or elevated chromogranin A (50%).